Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Warfarin
Drug ID BADD_D02373
Description Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.
Indications and Usage **Indicated** for:[label,L6616] 1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism. 2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation. 3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement. 4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction. **Off-label** uses include: 1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.[A179182]
Marketing Status approved
ATC Code B01AA03
DrugBank ID DB00682
KEGG ID D08682
MeSH ID D014859
PubChem ID 54678486
TTD Drug ID D0E3OF
NDC Product Code 76282-328; 43353-054; 65162-764; 70518-2381; 76282-335; 70518-2382; 76282-333; 43353-023; 51407-345; 65162-762; 65162-765; 70518-2383; 71335-1786; 65162-763; 65162-767; 68788-8402; 71610-491; 71610-519; 50090-2646; 50090-5058; 70518-2717; 71610-458; 71610-462; 43353-029; 50090-2936; 51407-346; 65162-769; 43353-030; 65162-768; 70518-2394; 71610-448; 71610-490; 76282-330; 50090-2613; 51407-342; 65162-766; 70518-2816; 76282-329; 76282-331; 76282-334; 50090-3263; 71335-1824; 76282-332; 43353-021; 43353-028; 43353-053; 51407-343; 51407-344; 51407-347; 65162-761; 76282-327; 43353-033; 50090-2645
UNII 5Q7ZVV76EI
Synonyms Warfarin | 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one | Apo-Warfarin | Aldocumar | Gen-Warfarin | Warfant | Coumadin | Marevan | Warfarin Potassium | Potassium, Warfarin | Warfarin Sodium | Sodium, Warfarin | Coumadine | Tedicumar
Chemical Information
Molecular Formula C19H16O4
CAS Registry Number 81-81-2
SMILES CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
IVth nerve paralysis17.04.02.007; 06.05.02.0200.000028%Not Available
Jugular vein thrombosis24.01.02.007--Not Available
Liposarcoma16.33.05.001; 15.09.03.0050.000028%Not Available
Locked-in syndrome17.01.04.0190.000028%Not Available
Lumbar spinal stenosis17.10.03.004; 15.10.04.0080.000028%Not Available
Mesenteric vein thrombosis24.01.08.004; 07.15.02.0130.000028%Not Available
Mitral valve stenosis02.07.01.0090.000056%Not Available
Myocardial fibrosis02.04.02.0160.000028%Not Available
Neonatal respiratory distress syndrome18.04.10.003; 22.11.02.0100.000070%Not Available
Normal newborn18.08.06.0010.000118%Not Available
Oesophageal ulcer haemorrhage24.07.02.051; 07.04.05.0070.000028%Not Available
Ovarian cyst ruptured21.11.01.015; 16.04.03.0060.000042%Not Available
Ovarian rupture21.11.02.0180.000056%
Pancreatitis relapsing07.18.01.0110.000042%Not Available
Prostatic haemorrhage24.07.03.028; 21.04.01.0090.000042%
Rectal adenocarcinoma07.21.05.005; 16.13.01.0160.000028%Not Available
Renal haematoma24.07.07.004; 20.01.02.018; 12.01.05.0060.000056%Not Available
Sciatic nerve palsy17.09.02.0150.000084%Not Available
Splenic haematoma24.07.01.079; 01.09.02.014; 12.01.17.0190.000056%Not Available
Splenic haemorrhage12.01.17.020; 24.07.01.080; 01.09.02.0150.000098%Not Available
Splenic vein thrombosis24.01.03.005; 01.09.02.0190.000042%Not Available
Tongue haematoma24.07.02.057; 07.14.01.0140.000084%Not Available
Urinary bladder haemorrhage24.07.01.086; 20.03.01.0230.000084%Not Available
Urinary bladder rupture20.03.01.024; 12.01.05.0070.000056%Not Available
Aneurysm ruptured24.02.01.0020.000070%Not Available
Atrial thrombosis02.11.01.002; 24.01.05.0050.000505%Not Available
Concomitant disease progression08.01.03.0640.000028%Not Available
Cerebral ventricle dilatation17.11.01.0130.000042%Not Available
Live birth18.08.02.0070.000210%Not Available
Tongue haemorrhage24.07.02.058; 07.14.01.0150.000042%Not Available
The 20th Page    First    Pre   20 21 22 23 24    Next   Last    Total 24 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene